New drugs and new toxicities: pembrolizumab-induced myocarditis
Sign Up to like & getrecommendations! Published in 2018 at "BMJ Case Reports"
DOI: 10.1136/bcr-2017-223252
Abstract: Pembrolizumab is an immune checkpoint inhibitor that significantly improves clinical outcomes in numerous solid organ malignancies. Despite successful therapeutic responses, this new drug comes with a constellation of adverse reactions. Herein, we chronicle the case… read more here.
Keywords: toxicities pembrolizumab; new toxicities; induced myocarditis; pembrolizumab induced ... See more keywords